• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Copley Scientific banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Business

Boehringer Ingelheim plans €170+ million expansion of Respimat production facilities

Boehringer Ingelheim has announced that it will spend over €100 million to increase production capacity for the Respimat inhaler at its Dortmund, Germany site to 44 million units per year. In addition, the company said, it will invest €72 million to expand its Respimat filling operations in Ingelheim. The Boehringer Ingelheim microParts site in Dortmund currently … [Read more...] about Boehringer Ingelheim plans €170+ million expansion of Respimat production facilities

Lightlake gets $1 million investment in two nasal spray products

According to Lightlake Therapeutics, an investor will receive a 0.98% interest in the company's naloxone nasal spray for the treatment of opioid overdose for a $500,000 investment and a 1% interest in intranasal naloxone for the treatment of binge eating disorder for an additional $500,000. In July 2014, the company filed an IND for the opioid reversal indication … [Read more...] about Lightlake gets $1 million investment in two nasal spray products

Discovery Labs gets up to $3 million to develop KL4 aerosol for the treatment of radiation induced lung damage

Discovery Laboratories has received a Phase 2 Small Business Innovation Research Grant (SBIR) from the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) for development of aerosolized KL4 surfactant for the treatment of lung damage caused by radiation. The initial award of $1 million can be supplemented by an … [Read more...] about Discovery Labs gets up to $3 million to develop KL4 aerosol for the treatment of radiation induced lung damage

Akorn acquires Sunovion’s Xopenex inhalation solution

Sunovion Pharmaceuticals has announced that it will sell "certain rights" to its Xopenex levalbuterol inhalation solution to Akorn for $45 million. Rights to the Xopenex HFA MDI are being retained by Sunovion. Akorn says that it will begin shipping the inhalation solution as soon as the deal is closed. Akorn CEO Raj Rai said, "We are excited to announce this … [Read more...] about Akorn acquires Sunovion’s Xopenex inhalation solution

Monash University to develop inhaled oxytocin in partnership with GSK

Monash University will license technology related to inhaled oxytocin for the treatment of postpartum hemorrhage to to GSK, the university and GSK have announced. Monash and GSK will collaborate on development through early clinical trials, including product optimization and manufacturing process development. Development of the dry powder formulation will be funded … [Read more...] about Monash University to develop inhaled oxytocin in partnership with GSK

Invion announces completion of first feasibility studies for inhaled nadolol

According to Invion, the company has successfully completed the first stage of feasibility studies for its INV102 inhaled nadolol, which it intends to develop for the treatment of asthma, COPD, and cystic fibrosis. Invion is partnered with 3M Drug Delivery Systems for development of INV102 and INV104, inhaled zafirlukast. Nadolol is a beta blocker normally used … [Read more...] about Invion announces completion of first feasibility studies for inhaled nadolol

Civitas Therapeutics to be acquired by Acorda

Acorda Therapeutics has announced that it will acquire inhaled drug developer Civitas Therapeutics, including rights to the ARCUS inhalation platform, for $525 million in cash. The deal includes worldwide rights to Civitas's lead candidate, CVT-301 inhaled L-dopa for the treatment of OFF episodes in Parkinson’s disease patients. Civitas CEO Mark Iwicki said, “We … [Read more...] about Civitas Therapeutics to be acquired by Acorda

Dr. Reddy’s launches generic Xopenex inhalation solution in the US

Dr. Reddy’s Laboratories have announced that the company has launched generic levalbuterol inhalation solution in the US as of September 23, 2014. The generic version of Sunovion's Xopenex is available in 0.31 mg /3 mL, 0.63 mg /3 mL, and 1.25 mg / 3 mL unit dose vials. Read the Dr. Reddy's press release. … [Read more...] about Dr. Reddy’s launches generic Xopenex inhalation solution in the US

Galen to market Penthrox inhaled methoxyflurane in the UK and Ireland

Almac subsidiary Galen Ltd will pay Medical Developments International (MVP) approximately A$650,000 (~US$587,000) up front for a license to market and distribute MVP's Penthrox inhaled methoxyflurane in the UK and Ireland. The deal also includes undisclosed regulatory and sales milestone payments. Penthrox, a non-opioid analgesic delivered via a proprietary vapor … [Read more...] about Galen to market Penthrox inhaled methoxyflurane in the UK and Ireland

Verona says that it can fund studies of RPL554 up to Phase 2b

In its most recent interim report, Verona Pharma says that it raised over £14 million pounds earlier this year which will allow it to continue development of its RPL554, an inhaled PDE3/PDE4 inhibitor, for the treatment of asthma and COPD. The company says that it is developing a new "commercially scalable" nebulized formulation of the drug. Previous testing has … [Read more...] about Verona says that it can fund studies of RPL554 up to Phase 2b

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 101
  • Page 102
  • Page 103
  • Page 104
  • Page 105
  • Interim pages omitted …
  • Page 152
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Proveris_180x150a
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews